Compare Citius Pharmaceuticals Inc (CTXR) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Redwire Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Redwire Corporation trades at $10.03 (market cap $2.33B). The key difference: Redwire Corporation is far larger — about 159.2× Citius Pharmaceuticals Inc's market cap, and Redwire Corporation is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | RDW | |
|---|---|---|
Market Cap | $14.64M | $2.33B |
Sector | Health | Technology |
52-Week High | $1.82 | $25.90 |
52-Week Low | $0.53 | $5.06 |
Enterprise Value | $10.86M | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
RDW trades at $9.59, down 5.8% with bearish technical signals despite 80% analyst buy ratings. The company shows significant revenue growth but deep losses, with net income margin at -80.9% and negative cash flow from operations. Recent news highlights dilution concerns from a $500M stock offering and competitive pressure from SpaceX's market dominance.
The stock presents high-risk potential with analyst consensus target of $19.00 representing 98% upside, but requires improved profitability and reduced cash burn. Key risks include persistent losses, dilution from financing activities, and intense space sector competition that could limit near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
